utah778/iStock through Getty Images
A federal courtroom in North Carolina has issued a preliminary injunction barring NeoGenomics Labs (NEO) from manufacturing and promoting its most cancers check, the RaDaR assay, in a patent lawsuit involving Natera (NASDAQ:NTRA).
Issuing a press launch late Wednesday, Natera (NTRA) stated that the federal District Court for the Middle District of North Carolina granted the preliminary injunction efficient instantly.
“The injunction bars NeoGenomics from “making, utilizing, promoting, or providing on the market within the United States… the accused RaDaR assay” or “any assay or product no more than colorably completely different” from the NeoGenomics RaDaR assay,” the corporate added.
However, the order would not forestall NeoGenomics (NEO) from providing the RaDaR assay for its present sufferers and for scientific trials.
The choice marks Natera’s (NTRA) second courtroom victory in current weeks. Early this month, a federal courtroom in Delaware issued a everlasting injunction in opposition to its rival Invitae Corporation (NVTA) after Natera (NTRA) alleged that the previous’s customized most cancers monitoring (PCM) merchandise violated its patents.
